FDA flexes its muscle

Several months ago, Packaging World/Healthcare Packaging legal columnist Eric Greenberg pointed out that the U.S. Food & Drug Administration would increase its activity in the new administration under Dr. Margaret Hamburg.

Hp 19159 1 Greenbergphoto
Recently, as PharmaManufacturing.com reported, the agency announced its “Transparency Initiative,” with a Transparency Task Force that aims to provide the public with timely, user-friendly information on FDA activities and decision-making. There's even a new FDA Basics Web site that's a bit less overwhelming than its main Web site.

Several recent FDA warnings about pharmaceutical warnings and recalls have arrived recently in this editor's e-mail in box. Perhaps the most prominent among these pertains to FDA's criticism of Johnson & Johnson's McNeil Consumer Healthcare Tylenol recalls, reportedly stemming from mold on wood pallets. In-Pharma Technologist.com reported last week that J&J expanded its U.S. drug recall due to more contamination fears. Greenberg, shown in the accompanying photo, will report on this matter in the February print issue of Healthcare Packaging.

-Jim Butschli
Fresh from the show floor: pharma packaging innovations for 2026
Serialization mandates. Containment demands. Sterile barrier requirements. Our editors found the pharma packaging innovations addressing your biggest challenges at PACK EXPO Las Vegas. Get your free curated report now.
GET YOUR COPY
Fresh from the show floor: pharma packaging innovations for 2026